Save 20% on your order with code
K4 Elite logo K4 Elite
Home / Peptide Library / Leuprolide
FDA Approved

Leuprolide

Hormonal & Endocrine · Leuprorelin, leuprolide acetate, LHRH agonist, GnRH agonist

Leuprolide is a synthetic nonapeptide analogue of gonadotropin-releasing hormone that acts as a GnRH receptor agonist; continuous receptor occupancy produces pituitary desensitisation and downstream suppression of gonadal steroid output in published models.

🔬 Research use only — not for human or veterinary use. K4 Elite does not provide dosing instructions.
Molecular Formula
C59H84N16O12
Molecular Weight
1209.4 g/mol
PubChem
CID 657181 ↗
Research Level
FDA Approved
Browse the store →
Leuprolide chemical structure

Leuprolide (also written leuprorelin) is a synthetic nonapeptide analogue of gonadotropin-releasing hormone (GnRH, also called LHRH). Its structure substitutes D-leucine at position 6 and replaces the C-terminal glycinamide with an ethylamide, two modifications that increase receptor affinity and greatly extend half-life relative to native GnRH.

It is one of the most extensively characterised peptides in endocrinology and is an approved pharmaceutical in multiple jurisdictions. The published literature covers hypothalamic-pituitary-gonadal axis physiology, receptor desensitisation kinetics, depot and sustained-release formulation science, and oncology and reproductive-endocrinology applications.

Because leuprolide is an approved prescription drug, most published human data comes from regulated clinical settings. This entry summarises the mechanistic and preclinical literature for research reference only and does not describe any human use.

Leuprolide binds the GnRH receptor on pituitary gonadotrophs. Native GnRH is released in pulses, and pulsatile receptor stimulation is what sustains luteinising hormone (LH) and follicle-stimulating hormone (FSH) secretion. Because leuprolide is long-acting, continuous exposure converts that pulsatile signal into a sustained one.

The literature describes a biphasic consequence: an initial agonist phase with a transient rise in LH, FSH and gonadal steroids (the so-called flare), followed by receptor downregulation and gonadotroph desensitisation, after which LH and FSH secretion falls and gonadal steroidogenesis is suppressed. This desensitisation behaviour is the mechanistic basis for the compound being used experimentally as a tool to reversibly suppress the reproductive axis in animal models.

  • GnRH receptor pharmacology. Binding affinity, agonist efficacy and receptor internalisation compared with native GnRH [1][2].
  • Pituitary desensitisation kinetics. Studies of the flare-then-suppression pattern in animal and cell models [1].
  • Hypothalamic-pituitary-gonadal axis physiology. Use as a research tool for reversible axis suppression in rodent and non-human models.
  • Sustained-release formulation science. Microsphere and implant depot literature examining release kinetics of the peptide [3].
  • Oncology and reproductive endocrinology. Large regulated clinical literature in hormone-sensitive disease, summarised in regulatory and reference databases [2][4].
  • Peptide stability. Structure-activity work on D-amino-acid substitution and C-terminal modification as strategies for protease resistance.
📋 How published studies were conducted — a research reference summarizing study designs from the literature. This is not usage, dosing, or administration guidance. K4 Elite does not provide dosing instructions; determining any research protocol is the sole responsibility of the qualified researcher.

Receptor-agonist characterisation. Model: pituitary gonadotroph preparations and GnRH receptor expression systems. Measure: LH and FSH release, receptor binding. Published work reports that continuous exposure to the long-acting analogue produces receptor downregulation and a fall in gonadotropin output, in contrast with the sustained output seen under pulsatile native GnRH stimulation [1].

Rodent axis-suppression models. Species/model: laboratory rodents. Measure: circulating LH, FSH and gonadal steroid concentrations. Studies describe an initial transient rise in gonadotropins followed by sustained suppression during continuous analogue exposure, with recovery after withdrawal; this reversibility is why the compound is used as an experimental axis-suppression tool [1][2].

Depot formulation release studies. Model: PLGA microsphere and in-situ implant systems, in vitro release and animal pharmacokinetic sampling. Measure: peptide release rate over time. The formulation literature characterises multi-week release profiles from biodegradable polymer matrices [3].

Regulatory pharmacology summaries. Source: drug label and reference-database pharmacology sections describing mechanism, suppression of ovarian and testicular steroidogenesis following continuous administration, and the initial stimulatory phase [2][4].

Combinations examined in the research literature. Descriptive only — not a recommendation to combine compounds.

TriptorelinCaution
Also a GnRH receptor agonist; overlapping mechanism means combined use in a model system is redundant and confounds interpretation.
GonadorelinCaution
Gonadorelin is native GnRH and is used to test pulsatile stimulation; a long-acting agonist opposes that experimental design.
Kisspeptin-10Caution
Kisspeptin acts upstream on GnRH neurons; downstream pituitary desensitisation by a GnRH agonist will blunt kisspeptin-driven responses in a model.
Cetrorelix and other GnRH antagonistsCaution
Antagonists block the same receptor without the initial agonist phase; the two classes oppose each other pharmacologically.
  1. PubChem CID 657181 - Leuprolide.
  2. NCATS Inxight Drugs - Leuprolide acetate record.
  3. ChEMBL compound record CHEMBL1201199 - Leuprolide.
  4. PubChem CID 3911 - Leuprelin acetate (salt form).
What class of peptide is leuprolide?
A synthetic nonapeptide GnRH (LHRH) receptor agonist, structurally derived from native gonadotropin-releasing hormone with a D-leucine substitution at position 6 and a C-terminal ethylamide.
Why does a GnRH agonist end up suppressing the axis?
Native GnRH signals in pulses. A long-acting agonist produces continuous receptor occupancy, which causes receptor downregulation and gonadotroph desensitisation, so LH and FSH output falls after an initial transient rise.
What is the flare effect described in the literature?
The initial agonist phase, during which LH, FSH and gonadal steroids transiently increase before desensitisation takes effect.
How does leuprolide differ from a GnRH antagonist?
Antagonists block the receptor directly and produce suppression without the initial stimulatory phase; agonists such as leuprolide suppress only after desensitisation develops.
Is this product intended for human use?
No. This material is supplied for laboratory research use only. It is not a drug, dietary supplement or medical device, and it is not for human or veterinary use.
Disclaimer: This profile summarizes published preclinical and laboratory research for reference only. It is not medical advice and makes no claim of safety or efficacy in humans. Determining any research protocol is the sole responsibility of the qualified researcher. Products are sold strictly for in-vitro research and have not been evaluated by the FDA.